(AOF) – Neovacs (+7.71% to 0.40 euro) is up sharply after announcing the presentation of new results on development projects for candidate vaccines in the field of asthma treatment at the Annual Congress of the European Molecular Biology Organization (Embo). The work presented testifies to the significant advances on these two programs (anti-IgE project and IL-4 and IL-13 project) for the treatment of asthma. In particular, the poster echoes the results recently published in the scientific journal Allergy.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.